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EXPRESSION OF COHESIN PROTEINS AND NANO-ARCHITECTURAL 
CHANGES IN RECTAL MUCOSA TO ASSESS RISK OF COLON CANCER 
BASED ON FIELD CARCINOGENESIS  
 
ARI B. DAVIS 
 
ABSTRACT 	  
With 50,310 related deaths this year, colorectal cancer (CRC) has emerged as the 
second largest cause of cancer related deaths among Americans. While 70 million 
Americans are considered at-risk of developing CRC, it is highly curable if detected 
early. Cohesin proteins, which hold sister chromatids together during replication, have 
emerged as a potential biomarker in multiple cancer lines. Because of their probable role 
in DNA replication, DNA repair, chromatin nanoarchitecture, and gene expression, this 
paper assessed whether cohesion proteins could be used as a potential biomarker for 
colorectal cancer risk stratification. While cohesin protein mutations have been reported 
in different cancers and involved in chromosomal instability, its role in early cancer 
formation has yet to be observed. Using immunohistochemical and Quantitative Real 
Time PCR analysis, this thesis assessed the protein and RNA expression levels of cohesin 
proteins SA-1, NIPBL, and SMC3 from human biopsies at different stages and locations 
of colorectal cancer development. The results showed that SA-1, a structural cohesion 
subunit, was significantly (p<0.01) down regulated in cancerous compared to normal 
tissue. The SA-1 protein was also down regulated in the involved mucosa adjacent to 
	  	   vii 
CRC polyps. The cohesion loading protein, NIPBL, was also significantly (p<0.01) under 
expressed in cancerous versus normal tissue. The RNA expression analysis of rectal 
mucosa showed that SMC3 and SA-1 was over expressed two fold in patients harboring 
hyperplastic and adenomous polyps, giving evidence that cohesin proteins are 
differentially expressed throughout the field of carcinogenesis. Our results demonstrate 
for the first time that cohesion dysregulation is an early event in human colorectal cancer 
development and may serve as an important biomarker of field carcinogenesis.  
  
	  	   viii 
TABLE OF CONTENTS 
 
TITLE……………………………………………………………………………………...i 
COPYRIGHT PAGE……………………………………………………………………...ii 
READER APPROVAL PAGE…………………………………………………………..iii 
DEDICATION ................................................................................................................... iv 
ACKNOWLEDGMENTS .................................................................................................. v 
ABSTRACT ....................................................................................................................... vi 
TABLE OF CONTENTS ................................................................................................ viiii 
LIST OF TABLES .............................................................................................................. x 
LIST OF FIGURES .......................................................................................................... xii 
LIST OF ABBREVIATIONS .......................................................................................... xiii 
I. INTRODUCTION ........................................................................................................... 1 
1.1 Background ........................................................................................................... 1 
1.2 Field Carcinogenesis ............................................................................................. 2 
1.3 Colorectal Biomarkers .......................................................................................... 3 
1.4 Cohesin as a Biomarker ........................................................................................ 6 
1.5 Specific Aims ........................................................................................................ 9 
II. METHODS ................................................................................................................... 10 
2.1 Experimental Design ........................................................................................... 10 
	  	   ix 
2.2 Experimental Techniques and Materials ............................................................. 12 
III. RESULTS ................................................................................................................... 16 
3.1 SA-1 and NIPBL are down regulated in CRC  ................................................... 16 
3.2 STAG1 and SMC3 are up regulated in field of cancer  ...................................... 20 
IV. DISCUSSION ............................................................................................................. 23 
APPENDIX ....................................................................................................................... 30 
LIST OF JOURNAL ABBREVIATIONS ........................................................................ 31 
REFERENCES ................................................................................................................. 32 
CURRICULUM VITAE ................................................................................................... 39 
 
  
	  	   x 
LIST OF TABLES 
 
Table Title Page 
1 Advanced Neoplastic Polyp Characterizations 15 
2 Percent Difference of SA-1 and SMC3 RNA Expression 21 
3 Cohesin RNA Expression in Ascending and Descending 
Colon 
21 
 
 
 
 
  
	  	   xi 
LIST OF FIGURES 
 
 
 
Figure Title Page 
1 Implication of CRC Biomarkers 4 
2 Structure of Cohesin Complex 9 
3 Cohesin (SA-1) Expression During Human Colon Cancer 17 
4 Immunohistochemical Positivity of Cohesin SA-1 in Colon 
Carcinogenesis 
18 
5 NIPBL and SA-1 Immunohistochemical Staining 19 
6 Cohesin (SA-1 and SMC3) RNA Expression 22 
           7          Deficiency and Impaired Telomere Function           24 
  
	  	   xii 
LIST OF ABBREVIATIONS 
 
ACF ......................................................................................... Adenomatosis polyposis coli 
BCP .................................................................................................. Bromo-3-cholopropane 
BMC ................................................................................................. Boston Medical Center 
cDNA ................................................................................................. Complementary DNA 
CIN ................................................................................................. Chromosomal instability 
CdLS ....................................................................................... Cornelia de Lange syndrome 
CRC ........................................................................................................... Colorectal cancer 
CTCF ................................................................................................. CCCTC binding factor 
EGF ................................................................................................. Epithelial growth factor 
IHC ................................................................................................... Immunohistochemistry 
PBS .............................................................................................. Phosphate buffered saline 
PCR ............................................................................................. Polymerase chain reaction  
SMC .................................................................................... Structural maintenance proteins 
 
 
 
	  1 
I. INTRODUCTION 
1.1 Background 
With approximately 50,310 deaths in 2014, colorectal cancer (CRC) has emerged 
as the second leading cause of cancer-related deaths in the United States and worldwide 
(Siegel et al., 2014.). The disease prognosis is highly dependent on the stage at which the 
disease is detected. While patients with localized CRC have a 5-year survival rate of up 
to 90%, the 5-year survival rate for patients with metastasized CRC can be as low as 8% 
(Coppedè, 2014). As well, while 25% of patients with CRC have a family history of the 
disease, the majority of cases (75%) are sporadic (Hudler et al., 2014). Because of these 
factors, it is widely accepted that the best approach to reducing the mortality rate is 
through a reduction of advanced disease by screening the average risk population. 
Modern screening procedures achieve this goal by the detection and removal of early-
stage neoplastic polyps. This ideology comes from the concept of the adenoma-
carcinoma sequence, a term that describes the step-wise progression of normal mucosa to 
carcinoma over a period where the tissue accumulates genetic and epigenetic alterations 
(Carey et al., 2002).  
Colorectal cancer screening options in the average-risk population fall into two 
main categories: stool tests that detect occult blood or exfoliated DNA and structural 
exams, which include flexible sigmoidoscopy, colonoscopy, and CT colography (virtual 
colonoscopy) exams. Fecal occult blood tests (FOBTs) have begun to decline in clinical 
use, partly due to it low sensitivity for advanced neoplastic polyps, which are defined as 
advanced adenomas and carcinomas (Roy et al., 2006). The virtual colonoscopy, while 
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showing promising results, is still undergoing validation studies and is unable to excise a 
polyp if found. The current gold standard for CRC screening is a colonoscopy procedure 
which directly inspects the mucosal lining of the entire colon and allows the clinician to 
evaluate and remove precancerous polyps. The American Cancer Society’s “Guidelines 
for the Early Detection of Cancer” recommends that beginning at the age of 50, men and 
women should begin structural colon examination. While this screening procedure is 
extremely effective in detecting advanced neoplastic lesions and reducing the incidence 
of CRC by 65%, only a quarter of the eligible screening population undergo a 
colonoscopy screening procedure (Roy et al., 2009). Of patients that have colonoscopies, 
only 20-30% have adenomas. In addition, the procedure is invasive and requires one or 
more days of dietary preparation and bowel cleansing with poor bowel prep leading to 
variable performance of the test. These factors can inhibit the ability of the procedure to 
detect polyps. A recent study (Singh et al., 2010) found that nearly 1 in 13 CRCs were 
missed on initial colonoscopic examination. With over 100 million Americans at risk of 
developing CRC along with the time, economic, and discomfort set backs of the current 
screening mechanism, it remains clear that an alternative prescreening approach needs to 
be implemented.  
 
1.2 Field carcinogenesis  
Field carcinogenesis  (also known as field effect or field cancerization) is a 
phenomenon that has many clinical implications for risk stratification. Field 
carcinogenesis is the idea that sequential genetic and environmental risk factors transform 
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an entire organ into a fertile zone for cells to undergo neoplasia and eventually tumor 
formation (Mutyal et al., 2013). While some cells in this mutational field become 
diagnosed histopathologically as a malignancy, it has been shown that other cells 
throughout the organ exposed to the same epigenetic and genetic factors display many of 
the same mutations as the cancerous cells (Backman et al, 2013). Therefore, these 
genetically transformed but histologically normal cells can be used to assess the risk of 
cancer formation. From a clinical perspective, field carcinogenesis has two main 
advantages in risk stratification. Since field carcinogenesis is not localized to a specific 
part of the colon, the markers for field carcinogenesis can be seen throughout the mucosa 
of the colon. Therefore, the rectal mucosa can be used as a surrogate site without the use 
of an endoscope or bowel purge. This would make screening less time intensive, more 
bearable for the patient, and less expensive. Secondly, since the genetic markers seen in 
field carcinogenesis throughout the mucosa of an organ are the precursors to neoplasia 
and tumor development, field carcinogenesis directly correlates to the risk of developing 
CRC. As opposed to attempting to preform colonoscopic procedures on the entire at risk 
population, which is remarkably inefficient with 6% of patients having advanced 
adenomas (Roy et al., 2009), using the field effect to pre-screen for patients at higher risk 
of developing CRC would highly increase the efficiency of screening and decrease the 
mortality of the disease. 
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1.3 Colorectal Biomarkers 
Colorectal cancer develops slowly through a complex series of changes in cellular 
proliferation and differentiation that transforms normal flat mucosa into 
adenocarcinomas, making the colon highly susceptible to the field effect (Fig. 1). The 
transformational stages are normal flat mucosa, aberrant crypt foci, adenoma with low-
grade dysplasia, adenoma with high-grade dysplasia, and adenocarcinoma (Bernstein et al  
 
2008). The cellular changes in histologically normal mucosa manifest themselves as 
micro and nan-architectural changes that effect gene expression and cellular processes 
and can be used as clinical biomarkers (Dakubo et al., 2007). These biomarkers can be 
	  	  
Figure	  1.	  Implication	  of	  CRC	  Biomarkers.	  The	  top	  panel	  shows	  H&E	  stains	  of	  different	  stages	  of	  CRC	  formation	  and	  information	  of	  key	  features	  at	  each	  stage.	  On	  the	  bottom	  panel	  is	  a	  graph	  of	  the	  5-­‐year	  survival	  rate	  (%)	  as	  CRC	  progresses	  and	  which	  types	  of	  biomarkers	  could	  be	  used	  at	  each	  stage	  of	  progression.	  This	  shows	  the	  importance	  of	  diagnostic	  and	  risk	  stratified	  biomarkers	  that	  can	  detect	  genomic	  instability	  and	  be	  able	  to	  differentiate	  non-­‐threatening	  polyps	  from	  progressive	  adenomas.	  Figure	  replicated	  from	  Jimenez	  et	  al.,	  2010	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classified into multiple distinct groups and their presence in distal normal appearing 
mucosa is predictive of adenomas elsewhere in the colon. 
• Morphological: The presence of rectal aberrant crypt foci (ACF) 
• Micro-architectural: Karyometrically identified nuclear parameters  
• Biochemically: Activity of protein kinase C (PKC), ornithine decarboxylase, and 
mucus disaccharide 
• Immunohistochemically: Loss of cytochrome c oxidase subunit I 
• Cellular: Increases in cellular proliferation and decreases in apoptosis (anti-
apoptotic protein Bc1-xL) 
• Genomics/Epigenetics: Differentially expressed genes using microarray analysis 
(cyclooxygenase 2, osteopontin, IGF-2, TGFα), hypermethylation of MGMT, etc.  
• Proteomics: Up-regulation and down-regulation of specific proteins (EB1, Pms2 
and or ERCC1) 
• Micro-vascular: expression of pre-angiogenic proteins (COX-2, iNOS, VEGF) 
While a plethora of potential biomarkers have been identified, few studies have 
attempted to validate the sensitivities and specificities of these biomarkers for use in a 
clinical setting. There are many reasons for the lag from discovery of biomarkers to use 
their clinical usage. One is the validation of novel biomarkers requires obtaining a large 
cohort of patients and most studies have small sample sizes. Validation of novel 
biomarkers also requires its study in all stages of cancer formation, specifically in pre-
malignant growth. Finally, most cancers progress through multiple carcinogenic 
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pathways which makes finding a biomarkers specific mechanism of action difficult to 
assess. Since CRC encompasses multiple phenotypes, it is widely accepted that multiple 
biomarkers are needed to aid in early detection and risk stratification of colorectal and 
other cancers through field carcinogenesis. 
 
1.4 Cohesin as a Biomarker 
 Recent research has validated that chromosomal instability (CIN) plays a major 
role in early CRC development (Barber et al., 2008). Chromosomal instability results in 
the loss or gain of entire or large regions of chromosomes, however the exact mechanism 
of action is poorly understood. This loss or gain in chromosomes could result in the 
removal of tumor suppressor genes or the gain of proto-oncogenes in a cell and 
consequentially cause abnormal growth and tumorigenesis. Recent studies have tried to 
determine whether whole chromosome missegregation results from errors in anaphase of 
mitosis (including defects in spindle assembly checkpoints, sister chromatid cohesion, 
kinetochore-microtubule (kMT) attachment, and chromosome number leading to lagging 
chromosomes or pre-mitotic replication stress generating partially replicated 
chromosomes (Bakhoum et al., 2014).  Results from a study analyzing the differences 
between CIN+ and CIN- cells found that the most frequent difference between the two 
cell lines was the presence of lagging chromosomes during anaphase (Bakoum et al. 
2014). The study also showed that repression of mitotic defects leading to lagging strands 
significantly represses CIN+ cells. If these mitotic defects can be targeted, it would 
enable future studies to identify the causes of early CRC development. 
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Recent studies have suggested that the cohesin family of proteins, which are 
essential in the chromosomal segregation process, could play a large factor in CIN. 
Cohesin is a multimeric complex made of structural maintenance proteins (SMC1 and 
SMC3), sister chromatid cohesion proteins (SA-1 and SA-2), and the chromatin loader 
(NIPBL) with the overall function of holding sister chromatids together from the time of 
replication in S phase until their separation in anaphase to ensure proper chromosome 
segregation during mitosis (Fig. 2). The SMC proteins are large polypeptides ranging 
from 1,000-1,300 amino acids with molecular weights ranging from 110-170kDa 
(Mannini et al., 2009). The ability of two SMC subunits to form a ring around DNA is 
due to the dimerization of the hinge domain that connects the subunits two coiled-coil 
domains. Besides its role in chromosomal segregation, cohesin proteins are emerging as a 
mechanism for regulating gene expression and maintenance of genome stability, which 
means that cohesion has many functions beyond what was first thought. Evidence of this 
concept comes from a study where Drosophila containing a mutation in cohesion loading 
protein NIPBL was found to be deficient in activation of homeobox genes. Additionally, 
cohesion has been found to regulate gene expression by interacting with the zinc-finger 
DNA binding protein, insulator protein CCCTC binding factor (CTCF) (Wendt et al., 
2008). In addition, SMC1 and SMC3 have also been identified as having a role in DNA 
repair and genome stability as part of the RC-1 complex which promotes the repair of 
DNA gaps and deletions (Xu et al., 2011). 
Observing that cohesin proteins play versatile functional roles in cellular 
processes, it comes as no surprise that cohesin and associated proteins have been found to 
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play a role in many cancer developments and other human disorders. The overexpression 
of the cohesion-binding protein WAPL, responsible for the timely release of cohesion 
from chromosome arms during prophase, has been observed in cervical cancers (Mannini 
et al., 2010). As well, WAPL down-regulation has been shown to inhibit the tumor 
growth in cervical cancer. Recent studies have found that mutations and deletions in  
SMC1 were found in patients suffering from Cornelia de Lange syndrome (CdLS) and in 
a range of tumors (Mannini et al., 2010). 
Since early CRC development is marked by chromosomal instability resulting in a 
sequence of epigenetic and genetic mutations that cause the activation of oncogenes and 
inactivation of tumor suppressor genes, the finding that cohesin related genes (SMC1, 
NIPBL, SMC3, STAG3) are mutated in early CRC development may explain the 
aneuploidy and enhanced rate of loss of heterozygosis seen in tumor progression. 
Specifically, a total of 11 different mutations of the SMC gene have been reported in 
colorectal cancers (Mannini, 2010). These mutations are all either missense or small-
inframe deletions that maintain the open reading frame of the gene resulting in a protein 
with residual function. Recognizing the role of cohesin, it is possible that these mutations 
might inhibit its ability to functionally load chromosomes by preventing hinge 
opening/dimerization or by interfering with gene expression. 
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Figure 2. Structure of Cohesin Complex. Above illustrates how the cohesin subunits 
interact together. The SMC1 and SMC3 structural maintenance proteins dimerize and 
after ATP hydrolysis, they form a ring around double stranded DNA during 
replication. On the bottom, a representation of how cohesin might form DNA loops 
and affects gene transcription by acting as an insulator. Figure is a replicate from 
Peters et al., 2012, “The many functions of cohesin—different rings to rule them all?” 
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1.5 Specific aims 
While mutations in genes encoding cohesin have been identified in CRC’s, 
expression levels of these proteins and associated genes in early cancer development have 
not been evaluated. In order to evaluate whether cells with impaired cohesion function 
cause chromosomal instability leading to early events in colorectal cancer formation, the 
level of cohesin expression from cancer related genes needs to be assessed. Using 
immunohistochemical analysis, our lab has shown early evidence that cohesion proteins 
SA-1 and NIPBL are down regulated early in human colorectal cancer (polyp stage). 
More importantly, evidence also supports that this down regulation is observed in 
adjacent tissue due to field carcinogenesis. In order to determine cohesin’s role in early 
colon carcinogenesis, this study also compared the gene expression of cohesion genes 
STAG1 (SA-1 protein) and SMC3 in human rectal biopsies to determine whether 
cohesion mediated chromosomal instability is a factor in early colon carcinogenesis. This 
data suggests that cohesion mediated chromosomal instability via epigenetic silencing 
could be a major pathway in early colon carcinogenesis. If this hypothesis can be 
verified, it would serve as a valuable biomarker for field carcinogenesis and risk 
assessment
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II. METHODS 	  
2.1 Experimental Design 
Immunohistochemical preparation. In this translational study, we assed 
whether or not cohesin could be contributing to early colorectal cancer progression. 
Using immunohistochemical analysis, we analyzed cohesin proteins SA-1, SMC3, and 
NIPBL from different grades of 72 tumors, 10 tumor-adjacent histologically normal 
tissue, and 10 control samples (non-CRC tissue).  
Patient screening. We assessed the gene expression levels of cohesin proteins 
SA-1 and SMC-3 in 50 human rectal mucosa samples obtained during a routine 
colonoscopy at the endoscopy unit at Boston Medical Center from September 2013 to 
March 2014. Biopsies were collected following the Institutional Review Board (IRB) 
guidelines after obtaining informed consent. There were 33 males (66%) and 17 females 
(34%). The mean ages were 56.1 years for males and 56.6 for females. Of all patients, 
27% had no polyps, 25% had hyperplastic polyps, 4% had serrated adenomas, 32% had 
tubular adenomas, and adenocarcinomas were present in 2% of patients. Of patients with 
hyperplastic polyps, 75% were found in the descending (left) colon, 33% were found in 
the transverse colon, and 8% were found in the ascending (right) colon. Of patients with 
pre-cancerous polyps, 44% were found in the descending colon, 50% were found in the 
ascending colon, and 6% were found in the transverse colon. 
Biopsy collection. Eligible patients were between 50-75 years of age and English-
speaking. Patients could not have a prior history of Inflammatory Bowel Disease, a 
personal history of colon neoplasia (polyps and/or cancer), or a genetic history of genetic 
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colon cancer syndromes (i.e. familial adenomatous polyposis, hereditary non-polyposis 
colon cancer. The research assistant administered a 5-minute questionnaire to the patient 
in the pre-procedure holding area at the Boston Medical Center Endoscopy Unit. The 
questionnaire estimates the risk for colonic neoplasia (high, normal, low) and has been 
used previously in the BMC population. Patients underwent the standard colonoscopy 
procedure under sedation as per usual care. The size, location, and morphology of all 
polyps excised were documented on a data collection sheet (Appendix A) and were later 
correlated to the corresponding pathology report which determined whether polyps were 
within the normal limits, hyperplastic, adenomas, or adenocarcinomas. Using the Boston 
Bowel Preparation Scale, the bowel cleanliness of the patient was also recorded on a 
scale of 0-3 (Appendix A). The gastroenterologist, using standard flexible endoscopy 
biopsy forceps, obtained rectal biopsies from histologically normal-appearing mucosa. 
For each patient, 6 punch biopsies roughly 1 millimeter thick were obtained 10 
centimeters above the anus. Biopsies were then transferred to 25mL of PBS and placed 
on dry ice before being stored long-term in a -80°C freezer. 
 
2.2 Experimental Techniques and Materials 
Immunohistochemistry. In order to determine which proteins to target for 
analysis, IHC staining was performed on human tissue arrays to analyze protein 
expression. Human CRC tissue arrays and CRC cell lines HT-29 (CIN+), HCT-116 
(CIN-) (US Biomax, Rockville, MD) were deparaffinized and then rehydrated with 
xylene and graded alcohol washes. After quenching of endogenous peroxidase activity in 
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3% hydrogen peroxide, the slides were blocked with 5% horse serum. The slides were 
incubated overnight in SA-1, SMC3, or NIPBL antibody (Sigma Life Science, Prestige 
Antibodies, St. Louis MO) followed by incubation with the appropriate biotinylated 
secondary antibody. The sections were then developed using an avidin-biotin complex kit 
(Vector Laboratories, Burlingame, CA). The intensity scoring was scaled from low to 
high on a scale of 0-3 by an observer. 
RNA isolation from colonic tissues. Samples stored at -80°C were thawed in an 
ice bath. Once thawed, the biopsies were transferred to 1.5mL tubes containing 1.5mm 
high impact zirconium beads (Denville Scientific Inc., NJ) and 0.5mL of TRI Reagent 
(Molecular Research Center Inc., Cincinnati, OH). The samples were then homogenized 
at room temperate using a BeadBug homogenizer (Benchmark Scientific, Edison, NJ). 
Total RNA was isolated from the homogenized tissue using a RiboPure Kit (Life 
Technologies, Woburn, MA) following the manufacturer’s instructions. Homogenized 
tissue was added to 100μL of bromochloropropane (BCP), vortexed at maximum speed 
for 15 seconds, and incubated at room temperature for 5 min. The samples were 
centrifuged at 12,000 x g for 10 min at 4°C to separate the mixture into a lower, red, 
organic phase, an interphase, and a colorless, upper, aqueous phase. The aqueous phase 
was transferred to a new 1.5mL microcentrifuge tube followed by the addition of 200μL 
100% ethanol (the organic and interphase were stored at a -80°C for later use). The 
samples were vortexed immediately at maximum speed for 5 seconds to avoid RNA 
precipitation. The samples were transferred to collection tubes with Filter Cartridges and 
centrifuged at 12,0000 x g for 30 seconds at room temperature until all the liquid was 
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through the filter. With the RNA bound to the Filter Cartridge, the flow through was 
discarded and 500μL of Wash Solution was added to the collection tube/Filter Cartridge 
assembly. The samples were centrifuged at 12,000 x g for 30 seconds at which time the 
flow through liquid was discarded. A second round of Wash Solution, centrifuging, and 
discarding of flow though, followed this. The Filter Cartridge with bound RNA was then 
transferred to a new collection tube. In order to elute the RNA, 45μL of Elution Buffer 
was added to the filter column and incubated at room temperate for 2 min. The collection 
tube was then centrifuged for 30 seconds at room temperate until the Elution Buffer 
containing RNA had flowed through the filter column. Quantification of RNA 
concentration was performed using the NanoDrop 2000 UV-Visiable Spectrophotometer 
(Thermo Scientific, Tewksbury, MA).  
Complementary DNA synthesis. Complementary DNA (cDNA) synthesis was 
performed using 10μL of standardized RNA and 10x reverse transcriptase buffer, 25x 
dNTP mix (100mM), 10x Random Primers, Multiscribe reverse transcriptase, RNase 
inhibitor, and RNase/DNase-free water in a Verti 96-Well Thermal Cycler (Life 
Technologies, Woburn, MA). 
 Quantitative Real Time-PCR analysis. Complementary DNA for all samples 
was standardized to 50ng/μL after quantification using the NanoDrop 2000 UV-Visiable 
Spectrophotometer. Each STAG1 and SMC3 PCR reaction was standardized to 50 ng/μL 
by combining 4 μL of cDNA product with the TaqMan probe and PCR Mastermix 
(Applied Biosystems, Carlsbad, CA). Real Time-PCR was performed using a StepOne 
Plus Real Time-PCR System (Life Technologies, Tewksbury, MA). All samples were 
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normalized to β-actin and average fold differences were calculated using the comparative 
Ct method (Livak, 2001). The threshold of fold change significance was set as >1.5 (up-
regulation) and <0.67 (down-regulation). 
 
Table 1. Advanced Neoplastic Polyp Characterizations. The sex, age, location, size, 
and pathology corresponding to the rectal biopsies collected .  
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III. RESULTS 	  
3.1 SA-1 and NIPBL are down regulated in CRC 
A recent proteomic study (Barber et al., 2008) found that human CRC cells carry 
multiple somatic mutations in genes that regulate cohesin proteins (SMC-1, NIPBL, SA-
3). Also, the knock out of these genes resulted in CIN. To determine if these cohesin 
proteins are associated with the early development of CRC, we first examined SA-1, SA-
2, SMC and NIPBL protein expression in human colon tissue specimens using 
immunohistochemical analysis. While 100% of control samples stained positively with 
SA-1 protein, that percentage dropped to 35% in cancerous samples (Fig. 4). To 
determine if the decrease in SA-1 expression was observed in CRC with chromosomal 
instability, CIN+ (HT-29) and CIN- (HCT-116) cell lines were tested for SA-1 
expression. We found that SA-1 expressed a 1.4 fold decrease in cell lines that were 
CIN+ compared to cell lines that were CIN-. Expression levels of SA-1 and NIPBL 
protein were found to be significantly under expressed in adenomas, malignant CRC, and 
metastatic CRC (P<0.01) (Fig. 3). To determine if SA-1 under expression was also 
observable in the field of carcinogenesis, expression levels of SA-1 of histologically 
normal appearing mucosa adjacent to an adenoma were examined and were also down 
regulated by 20% (Fig. 4). The intensity scoring for SA-2 expression showed very little 
reactivity in control samples and the expression of SMC3 did not significantly differ 
between cancer and control samples. 
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Figure 3. Immunohistochemical (IHC) analysis of the cohesin protein, SA-1, 
shows its expression intensity on a scale of low to high, 0 being the lowest and 
3.5 being the highest. IHC was performed on human tissue assays of varying 
degrees of carcinogenesis, normal colonic mucosa, and uninvolved mucosa 
adjacent to an adenoma.  	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Figure 4. This figure shows the percent of positively expressed SA-1 using 
immunohistochemistry in normal, uninvolved mucosa adjacent to an adenoma, 
adenoma, and adenocarcinoma human tissue. This represents the observation that 
SA-1 is down regulated early in CRC cancer formation and can be observed 
through the field effect. 
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Figure 5. NIPBL and SA-1 Immunohistochemical Staining. IHC staining of SA-1 and 
NIPBL was done on human tissue containing colonic adenocarcinomas and the tissue 
adjacent to the adenocarcinoma to determine if there was a histological difference seen in 
the field of cancer. 
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3.2 SA-1 and SMC3 are up regulated in the field of cancer 
In order to assess whether cohesin related genes are differentially expressed in the 
field of effect, the RNA expression levels of STAG1 (the gene encoding SA-1) and 
SMC3 from histologically normal rectal mucosa were evaluated using quantitative Real 
Time-PCR analysis. STAG1 was selected because of the significant results SA-1 showed 
from IHC analysis. While SMC3 was not significantly expressed during IHC analysis, 
other studies have shown that SMC3 is mutated in CRC. This along with the protein’s 
association with gene expression, DNA repair, and sister chromatid cohesion made it a 
viable choice. Additionally, SMC3 has been shown to be up regulated in CRC but not in 
the field of the cancer. The gene expression of SA-1 and SMC3 were up regulated nearly 
2 fold in the field of effect in patients harboring either hyperplastic or adenomous polyps 
as compared to the control (no dysplasia) (Fig. 6). The level of SA-1 expression was 
significantly increased in patients with hyperplastic polyps (P<0.05) and adenomous 
polyps (P<0.05). We then assessed whether there was difference between cohesion 
expression of patients with left versus right sided neoplasia and found that SMC3 
expression in patients with pre-cancerous growth was significantly (P<0.01) 
overexpressed in the descending colon; nearly a 500% increase (Tab. 3).  	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Table 2. Percent Difference of SA-1 and SMC3 RNA Expression. Using the 
comparative Ct method and quantitative PCR analysis (Livak, 2001), we compared 
the RNA expression of cohesin proteins in human rectal biopsies between patients 
with neoplastic, hyperplastic, or adenomous polyps to that of patients without any 
polyps. Cohesin protein SA-1 was statistically overexpressed in patients harboring 
any type of neoplastic polyp.  
* p < 0.05 Difference (% of control) 
 
 
                  SA-1 SMC-3 
Adenoma                    96* 99 
Hyperplastic                   109* 97 
Neoplastic                   118* 98 	  
Table 3. Cohesin RNA Expression in Ascending and Descending Colon. Using 
the comparative Ct method and quantitative PCR analysis (Livak, 2001), we 
compared the RNA expression of SA-1 and SMC proteins in human rectal biopsies 
between patients with neoplastic, hyperplastic, and adenomous polyps. SMC3 was 
significantly up regulated in the left, descending colon compared to the control. 
 
*p<0.05              Difference (% of control) 
 
 
                     SA-1 SMC3 
Left colon                       126   500* 
Right colon                       73   207* 
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Figure 6.  After quantification of SMC3 and SA-1 RNA expression using PCR-analysis, 
the fold change compared to control was assessed. While both SA-1 and SMC3 were 
overexpressed in rectal mucosal biopsies nearly 2 fold, only SA-1 was significantly up 
regulated in biopsies from patients with all types of polyp classifications.  	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IV. DISCUSSION 
In the world of personalized medicine, colorectal cancer is at the forefront of 
treatment. Using genomic analysis, we are now able to individually screen for patients for 
KRAS mutations, which informs clinicians that the patient will show resistance towards 
treatment with monoclonal antibody therapy cetuximab and panitumumab, drugs which 
target epidermal growth factor (EGFR). Recently, assays that detect DNA methylation 
biomarkers (genes that are abnormally repressed due to promoter methylation observed in 
CRC) have become commercially available. One of these assays, ColoVantage®, is a 
blood based test which is able to detect the presence of methylated septin 9 with an 
overall sensitivity of 90%. ColoSure 500 TM is also a commercially available fecal-based 
assay which detects methylation of the vimentin gene. In combination with a 
colonoscopy, this dual screening approach can reach a sensitivity of 88% (Hudler et al., 
2014). These and other assays currently undergoing clinical trials show that novel 
biomarkers are slowly becoming accepted as the standard in cancer risk stratification and 
detection. Novel nanotechnology and optical based sensors are allowing researchers to 
measure panels of specific cancer biomarkers with clinical implications. 
Using immunohistochemical and PCR analysis, we were able to show that not 
only are specific cohesin proteins differentially expressed at the genetic and protein level 
in pre-cancerous and cancerous samples, but these changes are also observable in 
adjacent tissue that is histologically normal. This supports prior studies that the field 
effect is a useful means of determining the presence of genetic and epigenetic changes 
throughout the colonic mucosa. Using immunohistochemical analysis, we found that the 
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SA-1 protein was significantly under expressed in human CRC tissue and showed a 
decrease in expression in adjacent, uninvolved tissue. In CIN+ cell lines, SA-1 expression 
was also decreased. This data supports the hypothesis that the SA-1 protein is down 
regulated in CRC and that it’s under expression might be causing chromosomal 
instability, creating a fertile zone throughout the mucosa for neoplastic growth. In 
accordance with other studies, SA-1 deficiency has found to be associated with 
aneuploidy and an increase in early tumourigenesis (Remeserio et al., 2012). Unlike SA-
2, which has been found to be critical for centromeric cohesion, this study showed that 
SA-1 has a specific role in telomere cohesion. This evidence suggests that a deficiency in 
SA-1 leads to fragile telomeres and prevents them from completely replicating (Fig. 7). 
This defect has been shown in mouse models to cause lagging chromosomes, which is 
consistent with Bachoum et al. that lagging chromosomes are a signature feature of CIN.  
 
	  
Figure 7. SA-1 Deficiency and Impaired Telomere Function. In SA-1 null cells, there 
is a lack of telomere cohesion leading to incomplete telomere replication and lagging 
chromosomes with the eventual cause of aneuploidy or cell death (Remeseiro et al. 2012) 
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Also of interest is the recent finding that SA-1 might play a large role in gene 
regulation. Cohesin SA-1 has been shown to localize at gene-associated regions of 
chromatin loops in the interphase nucleus, specifically promoter regions and replication 
origins (Cuadrado et al., 2012). Chromatin loops, one of the higher-order structures of 
genomic DNA, provide a suitable environment for processes such as DNA replication, 
transcription and repair.  In cells that lack SA-1, the cohesin complex was found to be 
much less likely to accumulate at promoters and replication origins with the chromatin 
insulator CTCF. The absence of cohesin and CTCF at promoters could alter the 
chromatin architecture and transcription of oncogenes and tumor suppressors, which was 
found to be the case in CdLS. Also, down-regulation of SA-1 at replication origins could 
slow down replication by limiting the number of active replication units and increasing 
the length of chromatin loops. The results from this study add dimension to prior studies 
on SA-1 by showing that SA-1 is not only under expressed in animal models, but also in 
human CRC. 
 The analysis of SA-1 protein expression differed from RNA expression of the 
STAG1 gene, which encodes the SA-1 protein. The results showed an increase in STAG1 
expression in rectal biopsies of patients who harbored adenomas. While multiple studies 
have identified an over expression of STAG1 in prostate, ovarian, and breast cancer 
(Giannini et al., 2003), it has not been reported in colorectal cancer. Research has shown 
that STAG1 is activated by the epidermal growth factor (EGF) pathway and plays a role 
in increased apoptosis. While this may be the mechanism STAG1 plays in the 
development of tumor formation, more research needs to be performed to validate this. 
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The results from this study identify that expression of the genetic/protein expression of 
STAG1 and SA-1 change throughout the course of cancer development. However, this 
could be to different lines of cancer development such as chromosomal instability, 
microsatellite instability, CpG island methylation and other genetic and epigenetic 
factors. Further research looking at the direct STAG1 pathway is needed to draw further 
conclusions. 
The finding that SMC3 was up-regulated in rectal mucosa from patients harboring 
neoplastic polyps is in accordance with other studies that have shown overexpression of 
SMC3 in fibroblasts (Ghiselli and Lozzo, 2000) which observed that the increase in 
SMC3 expression led to cellular transformation and proliferation. It is not unexpected 
that overexpression of SMC3 could be an early event in CRC cancer formation. The 
heterodimer SMC1A-SMC3 complex is the main structural component of cohesin. 
Laugsch et al. (2013) was able to show that when changes in SMC3 expression occur 
within a cell, the other component, SMC1A, becomes highly unstable and can only 
weakly associate with chromatin. This could have a large affect on cohesin’s role of 
keeping sister chromatids together during mitosis, eventually leading to an aneuploidy 
karyotype and chromosomal instability. The SMC1A-SMC3 complex is also a member of 
the recombination complex RC-1, which promotes DNA recombination. The RC-1 
complex is responsible for catalyzing several recombination related processes such as the 
connecting of single stranded DNA into double stranded DNA and the repair of 
gaps/deletions in double stranded DNA. Defects in the cohesin complex could affect the 
RC-1 complex’s ability to correctly catalyze these reactions. The SMC1A-SMC3 
	  27 
complex is also a component of the S phase DNA damage checkpoint, and deregulation 
of SMC3 could have negative consequences on its ability to repair damaged DNA. 
Perhaps most importantly, SMC3 overexpression has also been linked to activation of the 
APC/β-catenin/TCF4 pathway (Ghiselli et al., 2003). Mutations in the APC 
(adenomatosis polyposis coli) gene are found in more than 70% of colon adenomas and 
its loss of function is known to be an early event in colon cancer formation. Our data also 
showed that SMC3 was significantly overexpressed in the descending colon of patients 
harboring pre-cancerous polyps. This further supports our conclusion that cohesin 
contributes to CIN due to the fact that CIN implicated CRC is more common in the left, 
distal colon (Pritchard and Grady, 2011).   
The observation that NIPBL was under expressed in CRC tissue is also consistent 
with other studies. It has recently been observed that cohesin might have a role in gene 
activation by formation a DNA loop upon activation by a mediator protein. Upon being 
co-activated by the mediator protein, NIPBL loads cohesin onto DNA segments and is 
able to physically and functionally connect the promoter and enhancer regions of 
different genes. A reduction in expression of NIPBL could affect its ability to 
functionally load cohesin onto chromatin. This could result in CIN in two different ways: 
(1) a non-functional NIPBL could lead to missegreation of sister chromatids during 
mitosis and lead to aneuploidy or (2) it could cause improper DNA loop formation and 
therefor lead to certain tumor suppressor genes being overexpressed or proto-oncogenes 
being under expressed. The observation that mutated NIPBL has also been seen in 
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Cornelia de Lange syndrome as well as CRC suggests that NIPBL could possibly be a 
tumor suppressor gene (Kim et al., 2013). 
Since CRC with chromosomal instability is the most aggressive form of CRC, 
with a poor prognosis in 85%, this study represents a step forward in understanding how 
CIN develops. The finding that of 102 mutated genes related to CIN in colorectal cancer, 
25% were cohesin-related has prompted much research on how cohesin might affect CIN 
(Barber et al. 2008). While our findings shed no insight on the exact role the cohesin 
complex plays in cancer formation, it is clear that cohesin deregulation is an early event 
in colorectal cancer formation. It appears that there are two main possible mechanisms of 
how cohesin could cause CIN: (1) mutation of cohesin proteins leads to deregulation of 
specific cohesin proteins and causes loss of function in cohesion’s role to effectively hold 
sister chromatids together during replication, leading to incorrect separation of 
chromosomes and aneuploidy or (2) the deregulation is causing changes in chromatin 
architecture and negatively effecting gene expression. The results of this study have 
revealed that differential cohesin expression is an early event in human CRC formation, 
and that it could be a useful biomarker in field carcinogenesis. While this paper is one of 
the first to observe changes in cohesin expression at different stages of CRC, future 
studies are needed to further explain this observation. One drawback of this study is the 
small sample size of patients. A larger cohort of patients would allow a more robust 
analysis of cohesin expression at the hyperplastic, adenoma, and adenocarcinoma stage of 
CRC cancer. Also, future studies should examine cohesin expression in different 
phenotypes of CRC, specifically hereditary versus sporadic CRC. 
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The ability to identify early genetic and epigenetic events that lead to the clonal 
expansion of pre-neoplastic daughter cells in field effect poses as a promising future for 
colorectal cancer prevention. This study and studies of similar nature are answering the 
question of how exactly these cancer fields develop, and in doing so marks the first step 
towards understanding how to detect cancer before it even develops. 	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APPENDIX 
 
Appendix A. Data Collection Sheet. Collection sheet given to clinicians during routine 
standard of care colonoscopy to record any polyps excised and cleanliness of the bowel.  
Data Collection Sheet 
 
 
Study ID ________ 
 
 
PLEASE TAKE 6 RECTAL PUNCH BIOPSIES: 
 
• 10 cm above the anus 
• ~1 mm thick 
• Use provided forceps/jars for sample collection 
 
 
Extent of exam (circle):     CECUM      or         OTHER____________ 
 
 
Please list any polyps found during the exam: 
 
 
Location Bowel cleanliness 
(Boston Bowel 
Preparation Scale 
score)* 
# of polyps found Size(s) in mm 
Right colon 
 
 #1 
#2 
#3 
#4 
Transverse colon   #1 
#2 
#3 
#4 
Left colon   #1 
#2 
#3 
#4 
 
 
 
*Boston Bowl Preparation Scale 
3 = Colon/mucosa seen well with no residual staining/stool fragments 
2 = Colon/mucosa seen well with minor residual staining/stools fragments 
1 = Portion colon/colon seen due to residual staining/ stool fragments 
0 = Colon/mucosa unseen due to solid stool that cannot be cleared 
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